New Research Findings May Bring Breakthrough For Scleroderma Patients PDF Print E-mail
Monday, 01 October 2012 22:13
Research presented at the European Academy of Dermatology and Venereology in Prague, Czech Republic, suggests that inhibition of the SMAD protein may be a viable therapeutic target in Scleroderma patients.

This finding builds on previous research by presenter and lead researcher Donal O'Kane and colleagues showing that epidermal to mesenchymal transition (EMT) occurs in the skin of Scleroderma patients. This is most likely induced by high levels of the inflammatory cytokines transforming growth factor (TGF)-β and tumor necrosis factor (TNF)-α in sclerodermatous skin, and contributes directly to cutaneous fibrosis.

In the current study, O'Kane and team showed that SMAD inhibition weakens or reverses EMT in a normal human epidermal keratinocyte cell line. EMT was induced in the cells by the introduction of high levels of TGF-β and TNF-α to mimic conditions present in sclerodermatous human skin.

These findings could prove a real breakthrough for Scleroderma patients, as currently available treatments for Scleroderma are limited and often ineffective.

"At the minute because no treatments work effectively in clinical practice my feeling is that that's because they focus on fibrosis in the dermis as opposed to what predates that," O'Kane told medwireNews.

"The novel part of this EMT is we think that's before the fibrotic phase," he added, "so it gives a total new approach to the treatment of fibrotic disease and potentially will raise a lot more treatments as well."

To continue reading the full article, click here.

Source: Albert, H. (2012), "New treatment target brings hope for scleroderma patients"; News-medical.net;

 
More articles :

» Capillary Regeneration in Scleroderma: Stem Cell Therapy Reverses Phenotype?

Jo N. Fleming, Richard A. Nash, D. O. McLeod, David F. Fiorentino, Howard M. Shulman, M. Kari Connolly, Jerry A. Molitor, GretchenHenstorf, Robert Lafyatis, David K. Pritchard, Lawrence D. Adams, Daniel E. Furst, Stephen M....

» New Biomarker Predicts Poor Outcomes in Scleroderma

A novel biomarker may aid in establishing the prognosis of Systemic Sclerosis (Scleroderma), and particularly in predicting the most common lethal complications, an international group of researchers reported.Patients with Systemic Sclerosis who had...

» Finger Ulcers Still a Problem in Scleroderma

A significant number of patients with systemic sclerosis develop , greatly increasing their disease burden and the likelihood of complications, researchers reported here.For instance, 29.8% of patients with one or more digital ulcers developed...

» Happiness Makes For Healthier Hearts

People who are usually happy and enthusiastic are less likely to develop heart disease than those who tend to be glum, scientists said on Thursday, and boosting positive emotions could help cut heart health risks.U.S. researchers said their...

» Therapies for Scleroderma-related Pulmonary Arterial Hypertension

Paul M. HassounPosted: 08/20/2009; Expert Rev Resp Med. 2009;3(2):187-196. © 2009 Expert Reviews Ltd.Pulmonary arterial hypertension (PAH), a common complication of systemic sclerosis, carries a very severe prognosis and is one of the leading...

» Dysexecutive Syndrome A Specific Pattern of Cognitive Impairment in Systemic Sclerosis

Systemic sclerosis (SSc), also called scleroderma, is a connective-tissue disorder characterized by obliterative microvascular lesions and diffuse interstitial fibrosis. SSc damages the small and medium-sized vessels serving the skin, joints...